Liquid Biopsy has emerged as a minimally invasive diagnostic approach that enables real-time monitoring of cancer progression and treatment response through the analysis of circulating tumor components. This session will explore recent developments in circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other blood-based biomarkers used in cancer detection and management. Experts will discuss the clinical utility of liquid biopsy in early cancer diagnosis, therapy selection, disease monitoring, and recurrence detection. The session will also address technological innovations, analytical challenges, standardization efforts, and the future integration of liquid biopsy into routine oncology practice to support personalized and precision cancer care.
Sub tracks:
Liquid Biopsy Conferences